 Home > Active Ingredient News > Antitumor Therapy > BMC Cancer: Efficacy and safety of combined trastuzumab and fulvestrant in patients with HR+/HER2+ metastatic breast cancer

BMC Cancer: Efficacy and safety of combined trastuzumab and fulvestrant in patients with HR+/HER2+ metastatic breast cancer

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

3g 5 17

breast cancer marker blood test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Combination therapy with trastuzumab and fulvestrant is a treatment option for patients with hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, this combination therapy is currently being evaluated Efficacy studies are still limited
.

Therefore, there are retrospective studies abroad to evaluate the efficacy and safety of trastuzumab and fulvestrant in the treatment of patients with HR+/HER2+ metastatic breast cancer

Data were retrospectively collected from patients with HR+/HER2+ metastatic breast cancer who received the combination of trastuzumab and fulvestrant between August 1997 and August 2020
.

The primary endpoint of this study was progression-free survival, and secondary endpoints were response rate, overall survival, and safety

Data were retrospectively collected from patients with HR+/HER2+ metastatic breast cancer who received the combination of trastuzumab and fulvestrant between August 1997 and August 2020

The study screened data from 1612 patients with recurrent or metastatic breast cancer, 118 of whom were diagnosed with HR+/HER2+ breast cancer

Complete remission (CR) was not observed in all patients

The median progression-free survival (PFS) was 6.

PFS and OS

PFS subgroup analysis

In subgroup analysis, the median progression-free survival (PFS) was 7.
3 months (95% CI, 1.
53-18.
67) and the median OS was 7.
3 months (95% CI, 1.
53-18.
67) in patients treated with the combination of trastuzumab and fulvestrant as ≤3 lines of therapy Not reached
.

In contrast, patients treated as >3 lines had a median progression-free survival (PFS) of 5.

In subgroup analysis, the median progression-free survival (PFS) was 7.

Differences in PFS as different lines of treatment

In addition, patients with liver metastases had a shorter median PFS than those without liver metastases, 3.
5 months (95% CI, 1.
17-8.
93) and 6.
9 months (95% CI, 3.
93-8.
17), respectively (log rank test, p = 0.
3573)
.

In addition, patients with liver metastases had a shorter median PFS than those without liver metastases, 3.

Differences in PFS with and without liver metastases

No grade 3 adverse events were observed in the safety assessment
.

In conclusion, the study shows that the combination of trastuzumab and fulvestrant is safe and effective in the treatment of patients with HR+/HER2+ metastatic breast cancer, and can be used as an option after the progression of standard anti-HER2 therapy in this population
.

Studies have shown that the combination of trastuzumab and fulvestrant is safe and effective in patients with HR+/HER2+ metastatic breast cancer and can be used as an option after progression on standard anti-HER2 therapy in this population
.
Studies have shown that the combination of trastuzumab and fulvestrant is safe and effective in patients with HR+/HER2+ metastatic breast cancer and can be used as an option after progression on standard anti-HER2 therapy in this population
.

Original source:

Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, Hosonaga M, Fukada I, Hara F, Kobayashi T, Kobayashi K, Miyake S, Takano T , Ueno T, Ohno S.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
BMC Cancer.
2022 Jan 4;22(1):36 .
doi: 10.
1186/s12885-021-09128-1.
PMID: 34983437; PMCID: PMC8728947.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.